2023 Q1 Form 10-K Financial Statement

#000095017023010599 Filed on March 29, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.662M $898.7K $4.847M
YoY Change 130.77% 22.74% 109.65%
% of Gross Profit
Research & Development $1.232M $1.098M $4.412M
YoY Change 25.84% 28.3% 73.57%
% of Gross Profit
Depreciation & Amortization $6.840K $6.840K $27.36K
YoY Change 69.6% -32.81% 69.63%
% of Gross Profit
Operating Expenses $2.900M $2.004M $9.812M
YoY Change 70.56% 25.37% 101.46%
Operating Profit -$2.900M -$9.812M
YoY Change 70.56% 101.46%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $163.6K -$1.104M $63.67K
YoY Change -5523.73% 3401.9% -396.43%
Pretax Income -$2.736M -$3.108M -$12.24M
YoY Change 60.97% 90.69% 150.31%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$2.736M -$3.108M -$12.24M
YoY Change 60.65% 90.69% 150.31%
Net Earnings / Revenue
Basic Earnings Per Share -$0.28 -$4.73
Diluted Earnings Per Share -$0.28 -$0.29 -$4.73
COMMON SHARES
Basic Shares Outstanding 9.948M 2.590M
Diluted Shares Outstanding 9.722M 2.590M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.32M $5.934M $5.934M
YoY Change 36.72%
Cash & Equivalents $16.32M $5.934M $5.934M
Short-Term Investments
Other Short-Term Assets $1.012M $1.251M $1.251M
YoY Change 412.64%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $17.33M $7.185M $7.185M
YoY Change 56.73% 56.73%
LONG-TERM ASSETS
Property, Plant & Equipment $86.47K $93.31K $93.31K
YoY Change -22.67% -22.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $1.117M $1.117M
YoY Change 1181.59%
Total Long-Term Assets $86.47K $1.211M $1.211M
YoY Change 482.43% 482.44%
TOTAL ASSETS
Total Short-Term Assets $17.33M $7.185M $7.185M
Total Long-Term Assets $86.47K $1.211M $1.211M
Total Assets $17.42M $8.396M $8.396M
YoY Change 75.2% 75.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $541.8K $1.815M $1.815M
YoY Change 111.68% 111.68%
Accrued Expenses $724.7K $2.008M $2.008M
YoY Change 590.6% 590.59%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.266M $3.824M $3.824M
YoY Change 232.96% 232.96%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $12.97M $12.97M
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $12.97M $12.97M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.266M $3.824M $3.824M
Total Long-Term Liabilities $0.00 $12.97M $12.97M
Total Liabilities $1.266M $16.79M $16.79M
YoY Change 1361.98% 1361.98%
SHAREHOLDERS EQUITY
Retained Earnings -$20.61M -$17.87M
YoY Change 217.73%
Common Stock $996.00 $259.00
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $16.15M -$8.394M -$8.394M
YoY Change
Total Liabilities & Shareholders Equity $17.42M $8.396M $8.396M
YoY Change 75.2% 75.2%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$2.736M -$3.108M -$12.24M
YoY Change 60.65% 90.69% 150.31%
Depreciation, Depletion And Amortization $6.840K $6.840K $27.36K
YoY Change 69.6% -32.81% 69.63%
Cash From Operating Activities -$3.864M -$2.223M -$7.239M
YoY Change 94.68% 118.52% 85.47%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$390.0K -$525.0K
YoY Change
Cash From Investing Activities -$390.0K -$525.0K
YoY Change 283.77%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 14.25M -104.1K 9.358M
YoY Change -21947.26% -69.53% -2847.63%
NET CHANGE
Cash From Operating Activities -3.864M -2.223M -7.239M
Cash From Investing Activities -390.0K -525.0K
Cash From Financing Activities 14.25M -104.1K 9.358M
Net Change In Cash 10.39M -2.717M 1.594M
YoY Change -606.68% 99.95% -136.38%
FREE CASH FLOW
Cash From Operating Activities -$3.864M -$2.223M -$7.239M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$2.223M -$7.239M
YoY Change 118.52% 92.21%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
7500713
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
7500713
CY2022Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1756
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001835022
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-41583
CY2022 dei Entity Registrant Name
EntityRegistrantName
Coya Therapeutics, Inc.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-4017781
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
5850 San Felipe St., Suite 500
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77057
CY2022 dei City Area Code
CityAreaCode
800
CY2022 dei Local Phone Number
LocalPhoneNumber
587-8170
CY2022 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2022 dei Trading Symbol
TradingSymbol
COYA
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
0
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
9947915
CY2022 dei Auditor Firm
AuditorFirmId
410
CY2022 dei Auditor Name
AuditorName
Weaver and Tidwell, L.L.P.
CY2022 dei Auditor Location
AuditorLocation
Austin, Texas
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5933702
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4340178
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1251264
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
244080
CY2022Q4 us-gaap Assets Current
AssetsCurrent
7184966
CY2021Q4 us-gaap Assets Current
AssetsCurrent
4584258
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
93310
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
120671
CY2022Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
1117290
CY2021Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
87181
CY2022Q4 us-gaap Assets
Assets
8395566
CY2021Q4 us-gaap Assets
Assets
4792110
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1815270
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
857567
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2008361
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
290816
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3823631
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1148383
CY2022Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
12965480
CY2022Q4 us-gaap Liabilities
Liabilities
16789111
CY2021Q4 us-gaap Liabilities
Liabilities
1148383
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7500713
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7500713
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
7500713
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
7500713
CY2022Q4 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
10035954
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
8793637
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
8793637
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2590157
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2590157
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2590051
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2590051
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
259
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
259
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
681106
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
473602
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-17868547
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5623771
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-8393545
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
3643727
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8395566
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4792110
CY2022 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
4412498
CY2021 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2542135
CY2022 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
525000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4847080
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2312042
CY2022 us-gaap Depreciation
Depreciation
27361
CY2021 us-gaap Depreciation
Depreciation
16133
CY2022 us-gaap Operating Expenses
OperatingExpenses
9811939
CY2021 us-gaap Operating Expenses
OperatingExpenses
4870310
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-9811939
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-4870310
CY2022 coya Change In Fair Value Of Convertible Promissory Notes
ChangeInFairValueOfConvertiblePromissoryNotes
-2496510
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
63673
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-21482
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
317
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9357878
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-340584
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1593524
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-12244776
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-4891792
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.73
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.73
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.89
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.89
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2590173
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2590173
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2589832
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2589832
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
8301980
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
317
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
233222
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-4891792
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
3643727
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
158
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
207346
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-12244776
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-8393545
CY2022 us-gaap Profit Loss
ProfitLoss
-12244776
CY2021 us-gaap Profit Loss
ProfitLoss
-4891792
CY2022 us-gaap Depreciation
Depreciation
27361
CY2021 us-gaap Depreciation
Depreciation
16133
CY2022 coya Change In Fair Value Of Convertible Promissory Notes
ChangeInFairValueOfConvertiblePromissoryNotes
-2496510
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
207346
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
233222
CY2022 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
997367
CY2022 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
525000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
920002
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
216813
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
845284
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
665166
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
826556
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
290816
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7239354
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3903268
CY2022 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
525000
CY2021 coya Payments To Acquire Fixed Assets
PaymentsToAcquireFixedAssets
136804
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-525000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-136804
CY2022 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
10468970
CY2022 coya Payment Of Deferred Financing Costs Related To Initial Public Offering
PaymentOfDeferredFinancingCostsRelatedToInitialPublicOffering
113883
CY2022 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
997367
CY2021 us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
341901
CY2021 coya Proceeds From Founders For Subscription Receivable
ProceedsFromFoundersForSubscriptionReceivable
1000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
158
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4340178
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-4380656
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8720834
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5933702
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4340178
CY2022 coya Deferred Financing Costs In Accounts Payable And Accrued Expense
DeferredFinancingCostsInAccountsPayableAndAccruedExpense
1003408
CY2021 coya Deferred Financing Costs In Accounts Payable And Accrued Expense
DeferredFinancingCostsInAccountsPayableAndAccruedExpense
87181
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-17868547
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5933702
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the financial statements in the period they are determined to be necessary.</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Significant areas that require management’s estimates include fair value of the Company’s convertible promissory notes, the fair value of the Company's equity, prior to being publicly traded, and related inputs, including discount for lack of marketability and volatility, and the grant date fair value of stock options (Note 10), useful life of fixed assets and accrued research and development expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of credit risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash and cash equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2022Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
1117290
CY2022 us-gaap Intangible Assets Finite Lived Policy Costs Incurred To Renew Or Extend
IntangibleAssetsFiniteLivedPolicyCostsIncurredToRenewOrExtend
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Patent costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting expenses related to making such applications) and such costs of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120,992</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> were incurred during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, and 2021, respectively, which are included in general and administrative expenses in the accompanying statements of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022 us-gaap Short Term Lease Cost
ShortTermLeaseCost
30000
CY2021 us-gaap Short Term Lease Cost
ShortTermLeaseCost
150686
CY2022 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2021 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4624168
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1764551
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
10468970
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
2496510
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
12965480
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.09
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3M18D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
151433
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.48
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
28158
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.08
CY2022Q4 coya Prepaid Research And Development
PrepaidResearchAndDevelopment
175860
CY2021Q4 coya Prepaid Research And Development
PrepaidResearchAndDevelopment
200000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1051329
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
10033
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
24075
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
34047
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1251264
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
244080
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
136804
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
136804
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
43494
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
16133
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
93310
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
120671
CY2022 us-gaap Depreciation
Depreciation
27361
CY2021 us-gaap Depreciation
Depreciation
16133
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
146
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.08
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
478570
CY2022Q4 coya Accrued Research And Development
AccruedResearchAndDevelopment
135864
CY2021Q4 coya Accrued Research And Development
AccruedResearchAndDevelopment
163557
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
927006
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
105000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
945491
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
22259
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2008361
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
290816
CY2022Q2 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
20000000
CY2022 us-gaap Common Stock Voting Rights
CommonStockVotingRights
The holders of common stock are entitled to one vote for each share of common stock held at all meetings of stockholders. Unless required by law, there shall be no cumulative voting.
CY2022 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
one-for-5.6955
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
207346
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
233222
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
355441
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.85
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M12D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1384873
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
271098
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.38
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y4M24D
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
911713
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
478570
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
1.85
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y8M12D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
1384873
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
346417
CY2022 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y10M24D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.033
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y7M6D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8348
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
3.48
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 coya Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
0.046
CY2021 coya Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
0.011
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.164
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.199
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022Q4 coya Deferred Tax Assets Startup Costs
DeferredTaxAssetsStartupCosts
1502023
CY2021Q4 coya Deferred Tax Assets Startup Costs
DeferredTaxAssetsStartupCosts
557038
CY2022Q4 coya Deferred Tax Assets Capitalized License Fees
DeferredTaxAssetsCapitalizedLicenseFees
47250
CY2021Q4 coya Deferred Tax Assets Capitalized License Fees
DeferredTaxAssetsCapitalizedLicenseFees
44100
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
51795
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
43868
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
608738
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
494955
CY2022Q4 coya Deferred Tax Assets Tax Deferred Expense Accrued Expenses And Other
DeferredTaxAssetsTaxDeferredExpenseAccruedExpensesAndOther
60521
CY2022Q4 coya Deferred Tax Assets Section174 Capitalization
DeferredTaxAssetsSection174Capitalization
873687
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
3143954
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1137603
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
60
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
2358
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
60
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
2358
CY2022Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
60
CY2021Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
2358
CY2022 coya Consulting Fees
ConsultingFees
30000
CY2021 coya Consulting Fees
ConsultingFees
127500

Files In Submission

Name View Source Status
0000950170-23-010599-index-headers.html Edgar Link pending
0000950170-23-010599-index.html Edgar Link pending
0000950170-23-010599.txt Edgar Link pending
0000950170-23-010599-xbrl.zip Edgar Link pending
coya-20221231.htm Edgar Link pending
coya-20221231.xsd Edgar Link pending
coya-ex31_1.htm Edgar Link pending
coya-ex31_2.htm Edgar Link pending
coya-ex32_1.htm Edgar Link pending
coya-ex3_1.htm Edgar Link pending
coya-ex3_2.htm Edgar Link pending
coya-ex4_6.htm Edgar Link pending
coya-20221231_cal.xml Edgar Link unprocessable
coya-20221231_def.xml Edgar Link unprocessable
coya-20221231_lab.xml Edgar Link unprocessable
coya-20221231_pre.xml Edgar Link unprocessable
coya-20221231_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img267772790_0.jpg Edgar Link pending
img267772790_1.jpg Edgar Link pending
img267772790_10.jpg Edgar Link pending
img267772790_11.jpg Edgar Link pending
img267772790_12.jpg Edgar Link pending
img267772790_13.jpg Edgar Link pending
img267772790_14.jpg Edgar Link pending
img267772790_15.jpg Edgar Link pending
img267772790_16.jpg Edgar Link pending
img267772790_17.jpg Edgar Link pending
img267772790_2.jpg Edgar Link pending
img267772790_3.jpg Edgar Link pending
img267772790_4.jpg Edgar Link pending
img267772790_5.jpg Edgar Link pending
img267772790_6.jpg Edgar Link pending
img267772790_7.jpg Edgar Link pending
img267772790_8.jpg Edgar Link pending
img267772790_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending